Established and emerging therapies for the treatment of viral hepatitis

被引：8
作者：
Forton, Daniel
Karayiannis, Peter
机构：
[1] Imperial Coll London, Fac Med, Dept Med A, Hepatol Sect, London W2 1NY, England
[2] Imperial Coll, Dept Med A, London, England
来源：
DIGESTIVE DISEASES | 2006年 / 24卷 / 1-2期
关键词：
hepatitis B virus; hepatitis C virus; treatment; interferon; pegylated interferon; antivirals nucleos(t)ide analogues; lamivudine; adefovir dipivoxil; ribavirin; resistance;
D O I：
10.1159/000090319
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Patients who are chronically infected with either hepatitis B or C viruses run the risk of developing cirrhosis and hepatocellular carcinoma in later life. Antiviral treatment offers the only means of interrupting this progression. To date, recombinant interferon alpha and the nucleos(t)ide analogues lamivudine and adefovir dipivoxil are the only licensed drugs for the treatment of chronic hepatitis B, whilst recombinant or pegylated interferons in combination with ribavirin are the ones used for chronic hepatitis C virus infections. The efficacy of these treatments, reasons for treatment failure, drug resistance and future options are discussed in the present review. Copyright (c) 2006 S. Karger AG, Basel.
引用
收藏
页码：160 / 173
页数：14
相关论文
共 139 条
[31]   Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine [J].
Di Marco, V ;
Marzano, A ;
Lampertico, P ;
Andreone, P ;
Santantonio, T ;
Ahnasio, PL ;
Rizzetto, M ;
Craxì, A .
HEPATOLOGY, 2004, 40 (04) :883-891
[32]   Influence of HIV infection on the response to interferon therapy and the long-term outcome of chronic hepatitis B [J].
Di Martino, V ;
Thevenot, T ;
Colin, JF ;
Boyer, N ;
Martinot, M ;
Degos, F ;
Coulaud, JP ;
Vilde, JL ;
Vachon, F ;
Degott, C ;
Valla, D ;
Marcellin, P .
GASTROENTEROLOGY, 2002, 123 (06) :1812-1822
[33]  
DIBISCEGLIE AM, 1991, HEPATOLOGY, V14, P969, DOI 10.1016/0270-9139(91)90113-A
[34]   RIBAVIRIN AS THERAPY FOR CHRONIC HEPATITIS-C - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
DIBISCEGLIE, AM ;
CONJEEVARAM, HS ;
FRIED, MW ;
SALLIE, R ;
PARK, Y ;
YURDAYDIN, C ;
SWAIN, M ;
KLEINER, DE ;
MAHANEY, K ;
HOOFNAGLE, JH ;
WRIGHT, D .
ANNALS OF INTERNAL MEDICINE, 1995, 123 (12) :897-&
[35]   Durability of serologic response after lamivudine treatment of chronic hepatitis B [J].
Dienstag, JL ;
Cianciara, J ;
Karayalcin, S ;
Kowdley, KV ;
Willems, B ;
Plisek, S ;
Woessner, M ;
Gardner, S ;
Schiff, E .
HEPATOLOGY, 2003, 37 (04) :748-755
[36]   Lamivudine as initial treatment for chronic hepatitis B in the United States [J].
Dienstag, JL ;
Schiff, ER ;
Wright, TL ;
Perrillo, RP ;
Hann, HWL ;
Goodman, Z ;
Crowther, L ;
Condreay, LD ;
Woessner, M ;
Rubin, M ;
Brown, NA .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (17) :1256-1263
[37]   Dual efficacy of lamivudine treatment in human immunodeficiency virus/hepatitis B virus-coinfected persons in a randomized, controlled study (CAESAR) [J].
Dore, GJ ;
Cooper, DA ;
Barrett, C ;
Goh, LE ;
Thakrar, B ;
Atkins, M .
JOURNAL OF INFECTIOUS DISEASES, 1999, 180 (03) :607-613
[38]   Mutations of the core promoter and response to interferon treatment in chronic replicative hepatitis B [J].
Erhardt, A ;
Reineke, U ;
Blondin, D ;
Gerlich, WH ;
Adams, O ;
Heintges, T ;
Niederau, C ;
Haussinger, D .
HEPATOLOGY, 2000, 31 (03) :716-725
[39]   Determinants of early mortality in patients with decompensated chronic hepatitis B treated with antiviral therapy [J].
Fontana, RJ ;
Hann, HWL ;
Perrillo, RP ;
Vierling, JM ;
Wright, T ;
Rakela, J ;
Anschuetz, G ;
Davis, R ;
Gardner, SD ;
Brown, NA .
GASTROENTEROLOGY, 2002, 123 (03) :719-727
[40]   Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B [J].
Fontana, RJ ;
Keeffe, EB ;
Carey, W ;
Fried, M ;
Reddy, R ;
Kowdley, KV ;
Soldevila-Pico, C ;
McClure, LA ;
Lok, ASF .
LIVER TRANSPLANTATION, 2002, 8 (05) :433-439
12345678910